FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

Humanin

HN / HNG / Humanin G

Longevity & Anti-Aging

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA, first discovered in 2001 from surviving neurons in Alzheimer's disease brains. It exhibits potent neuroprotective, anti-apoptotic, and cytoprotective properties across multiple organ systems through interactions with IGFBP-3, BAX, and the formyl peptide receptor-like 1 (FPRL1). Research interest has expanded from neurodegeneration to encompass metabolic disease, cardiovascular protection, and aging biology.

Mechanism of Action

Mitochondria-derived micropeptide encoded in the 16S rRNA region. Neuroprotective through binding to IGFBP-3 (blocking apoptosis), activating STAT3 signaling, and modulating BAX-mediated cell death. Also improves insulin sensitivity and reduces amyloid-beta toxicity.

Research Protocols

For research purposes only. Not medical advice.

Research protocols are primarily preclinical. Humanin analogs (HNG, HNGF6A) used at 1-4mg/kg in animal models. Human dosing not established. Intranasal and subcutaneous routes studied.

Research Notes

Clinical Research Status

Humanin remains in the preclinical and early translational research phase, with no completed human clinical trials as of current literature. Observational studies have found that circulating humanin levels decline with age and correlate inversely with markers of cognitive decline and metabolic dysfunction. Several humanin analogs with enhanced potency and stability, particularly HNG (S14G-Humanin), have been developed to overcome the native peptide's short half-life and advance toward clinical testing.

Key Published Findings

The original discovery by Bhimori Hashimoto (2001) demonstrated that humanin specifically protected neurons against amyloid-beta toxicity, presenilin mutant-induced apoptosis, and other Alzheimer's-related insults. Subsequent research revealed humanin acts as an insulin sensitizer, reducing hepatic glucose production and improving glucose tolerance in animal models of diabetes. Studies in cardiovascular models show humanin protects against ischemia-reperfusion injury, reduces atherosclerotic plaque formation, and inhibits vascular smooth muscle cell apoptosis.

Safety Profile

As an endogenously produced peptide, humanin is considered to have a favorable safety profile, though systematic toxicology studies in humans have not been conducted. The primary theoretical concern involves its anti-apoptotic properties potentially interfering with tumor suppression mechanisms, though some evidence suggests it may actually enhance certain anti-cancer immune responses. No significant adverse effects have been reported in animal studies at supraphysiological doses, though long-term exposure data remains limited.

Comparison to Related Compounds

Humanin is the founding member of the mitochondrial-derived peptide family, which also includes MOTS-c (a 16-amino acid exercise mimetic peptide) and the SHLPs (Small Humanin-Like Peptides 1-6). Unlike exogenous neuroprotective peptides such as Cerebrolysin or Semax, humanin represents an endogenous protective signal that declines with mitochondrial aging. The analog HNG is approximately 1000-fold more potent than native humanin, making it more practical for research applications.

Community Observations

Interest in humanin within longevity research communities centers on its role as a biomarker and potential therapeutic for mitochondrial aging. Due to extremely limited commercial availability and the early stage of research, human experimentation outside academic settings is rare. The peptide's connection to centenarian genetics (elevated humanin levels correlate with exceptional longevity) has generated significant interest in the anti-aging research community.

Half Life

~30-60 minutes

Reconstitution

Sterile saline or bacteriostatic water

Storage

Lyophilized

Store at -20C. Sensitive to freeze-thaw cycles.

Reconstituted

Refrigerate 2-8C. Use within 7 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

HNHNGHumanin G

Frequently Asked Questions

What is Humanin?

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA, first discovered in 2001 from surviving neurons in Alzheimer's disease brains. It exhibits potent neuroprotective, anti-apoptotic, and cytoprotective properties across multiple organ systems through interactions with IGFBP-3, BAX, and the formyl peptide receptor-like 1 (FPRL1). Research interest has expanded from neurodegeneration to encompass metabolic disease, cardiovascular protection, and aging biology.

How does Humanin work?

Mitochondria-derived micropeptide encoded in the 16S rRNA region. Neuroprotective through binding to IGFBP-3 (blocking apoptosis), activating STAT3 signaling, and modulating BAX-mediated cell death. Also improves insulin sensitivity and reduces amyloid-beta toxicity.

What is the US regulatory status of Humanin?

Research chemical (not FDA-approved)

What is the half-life of Humanin?

~30-60 minutes

What else is Humanin called?

HN, HNG, Humanin G

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer